Novartis’ CAR-T therapy gets second FDA approval – PharmaTimes
PharmaTimes |
Novartis' CAR–T therapy gets second FDA approval
PharmaTimes The FDA has approved Novartis' CAR-T therapy Kymriah (tisagenlecleucel) for intravenous infusion for its second indication – the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic … Two major advances for CAR T-cell cancer treatment FDA Approves CAR-T Cell Therapy for Diffuse Large B-Cell … Novartis and Gilead's CAR–T Therapies Now Compete for the Same Cancer Patients |
